{"id":60589,"date":"2019-05-09T11:15:12","date_gmt":"2019-05-09T11:15:12","guid":{"rendered":"https:\/\/lmcca.wpengine.com\/?p=60589"},"modified":"2019-05-09T11:16:19","modified_gmt":"2019-05-09T11:16:19","slug":"first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/www.lmc.ca\/fr\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/","title":{"rendered":"Premi\u00e8re \u00e9valuation de la performance d'un syst\u00e8me implantable de surveillance continue du glucose pendant 180 jours dans une population principalement compos\u00e9e d'adolescents atteints de diab\u00e8te de type 1"},"content":{"rendered":"<p>[et_pb_section bb_built=&#8221;1&#8243;][et_pb_row][et_pb_column type=&#8221;4_4&#8243;][et_pb_text _builder_version=&#8221;3.21.1&#8243; z_index_tablet=&#8221;500&#8243;]<\/p>\n<h3 class=\"p1\"><span class=\"s1\">This month, our newest publication is the full report of the Eversense study results.\u00a0 Eversense is the very nifty sensor that is implanted subcutaneously and provides continuous glucose monitoring to your phone for 6 months.\u00a0 Our results were in teenagers &#8211; the first pediatric study \u2013 and were the first to verify the full 180-day lifespan of this generation of the device, and the first in a Pediatric population.\u00a0 The results were presented by Dr. Alex Abitbol and Dr. Ronnie Aronson at the EASD and ADA sessions last year.<\/span><\/h3>\n<p>\u00a0<\/p>\n<h3 class=\"p1\"><span class=\"s1\">Read the publication here:<\/span><\/h3>\n<h3><span style=\"color: #97a822;\"><a style=\"color: #97a822;\" href=\"https:\/\/lmc.ca\/wp-content\/uploads\/2019\/05\/Aronson-et-al-2019-Eversense-Pediatric-180-day-study-Diabetes-Obesity-Metabolism-1-1.pdf\"><strong>First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes<\/strong><\/a><\/span><\/h3>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p><div class=\"et_pb_row et_pb_row_0 et_pb_row_empty\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div> This month, our newest publication is the full report of the Eversense study results.\u00a0 Eversense is the very nifty sensor that is implanted subcutaneously and provides continuous glucose monitoring to your phone for 6 months.\u00a0 Our results were in teenagers &#8211; the first pediatric study \u2013 and were the first to verify the full [&hellip;]<\/p>\n","protected":false},"author":25,"featured_media":60590,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","two_page_speed":[],"footnotes":""},"categories":[163],"tags":[265,126,266,103],"class_list":["post-60589","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-clinical","tag-clinical-research","tag-diabetes-resea","tag-type-1-diabetes"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes - LMC Healthcare: Helping You Understand and Control your Diabetes<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lmc.ca\/fr\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes - LMC Healthcare: Helping You Understand and Control your Diabetes\" \/>\n<meta property=\"og:description\" content=\"This month, our newest publication is the full report of the Eversense study results.\u00a0 Eversense is the very nifty sensor that is implanted subcutaneously and provides continuous glucose monitoring to your phone for 6 months.\u00a0 Our results were in teenagers - the first pediatric study \u2013 and were the first to verify the full [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lmc.ca\/fr\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"LMC Healthcare: Helping You Understand and Control your Diabetes\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LMCDiabetesandEndocrinology\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-09T11:15:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-05-09T11:16:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/05\/Screen-Shot-2019-05-09-at-12.05.31-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1567\" \/>\n\t<meta property=\"og:image:height\" content=\"580\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"LMC Healthcare\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lmc_diabetes\" \/>\n<meta name=\"twitter:site\" content=\"@lmc_diabetes\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LMC Healthcare\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/\"},\"author\":{\"name\":\"LMC Healthcare\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#\\\/schema\\\/person\\\/0d459c76f19eec906969bebe87612783\"},\"headline\":\"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes\",\"datePublished\":\"2019-05-09T11:15:12+00:00\",\"dateModified\":\"2019-05-09T11:16:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/\"},\"wordCount\":167,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/Screen-Shot-2019-05-09-at-12.05.31-PM.png\",\"keywords\":[\"clinical\",\"clinical research\",\"diabetes resea\",\"type 1 diabetes\"],\"articleSection\":[\"News\"],\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/\",\"url\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/\",\"name\":\"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes - LMC Healthcare: Helping You Understand and Control your Diabetes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/Screen-Shot-2019-05-09-at-12.05.31-PM.png\",\"datePublished\":\"2019-05-09T11:15:12+00:00\",\"dateModified\":\"2019-05-09T11:16:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#\\\/schema\\\/person\\\/0d459c76f19eec906969bebe87612783\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/Screen-Shot-2019-05-09-at-12.05.31-PM.png\",\"contentUrl\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/Screen-Shot-2019-05-09-at-12.05.31-PM.png\",\"width\":1567,\"height\":580},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/news\\\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.lmc.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.lmc.ca\\\/\",\"name\":\"LMC Healthcare: Helping You Understand and Control your Diabetes\",\"description\":\"Consulting Design Engineers\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.lmc.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#\\\/schema\\\/person\\\/0d459c76f19eec906969bebe87612783\",\"name\":\"LMC Healthcare\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g\",\"caption\":\"LMC Healthcare\"},\"url\":\"https:\\\/\\\/www.lmc.ca\\\/fr\\\/author\\\/andrea\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes - LMC Healthcare: Helping You Understand and Control your Diabetes","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lmc.ca\/fr\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/","og_locale":"fr_CA","og_type":"article","og_title":"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes - LMC Healthcare: Helping You Understand and Control your Diabetes","og_description":"This month, our newest publication is the full report of the Eversense study results.\u00a0 Eversense is the very nifty sensor that is implanted subcutaneously and provides continuous glucose monitoring to your phone for 6 months.\u00a0 Our results were in teenagers - the first pediatric study \u2013 and were the first to verify the full [&hellip;]","og_url":"https:\/\/www.lmc.ca\/fr\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/","og_site_name":"LMC Healthcare: Helping You Understand and Control your Diabetes","article_publisher":"https:\/\/www.facebook.com\/LMCDiabetesandEndocrinology\/","article_published_time":"2019-05-09T11:15:12+00:00","article_modified_time":"2019-05-09T11:16:19+00:00","og_image":[{"width":1567,"height":580,"url":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/05\/Screen-Shot-2019-05-09-at-12.05.31-PM.png","type":"image\/png"}],"author":"LMC Healthcare","twitter_card":"summary_large_image","twitter_creator":"@lmc_diabetes","twitter_site":"@lmc_diabetes","twitter_misc":{"Written by":"LMC Healthcare","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#article","isPartOf":{"@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/"},"author":{"name":"LMC Healthcare","@id":"https:\/\/www.lmc.ca\/#\/schema\/person\/0d459c76f19eec906969bebe87612783"},"headline":"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes","datePublished":"2019-05-09T11:15:12+00:00","dateModified":"2019-05-09T11:16:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/"},"wordCount":167,"commentCount":0,"image":{"@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/05\/Screen-Shot-2019-05-09-at-12.05.31-PM.png","keywords":["clinical","clinical research","diabetes resea","type 1 diabetes"],"articleSection":["News"],"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/","url":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/","name":"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes - LMC Healthcare: Helping You Understand and Control your Diabetes","isPartOf":{"@id":"https:\/\/www.lmc.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/05\/Screen-Shot-2019-05-09-at-12.05.31-PM.png","datePublished":"2019-05-09T11:15:12+00:00","dateModified":"2019-05-09T11:16:19+00:00","author":{"@id":"https:\/\/www.lmc.ca\/#\/schema\/person\/0d459c76f19eec906969bebe87612783"},"breadcrumb":{"@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#primaryimage","url":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/05\/Screen-Shot-2019-05-09-at-12.05.31-PM.png","contentUrl":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/05\/Screen-Shot-2019-05-09-at-12.05.31-PM.png","width":1567,"height":580},{"@type":"BreadcrumbList","@id":"https:\/\/www.lmc.ca\/it\/news\/first-assessment-of-the-performance-of-an-implantable-continuous-glucose-monitoring-system-through-180-days-in-a-primarily-adolescent-population-with-type-1-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lmc.ca\/"},{"@type":"ListItem","position":2,"name":"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes"}]},{"@type":"WebSite","@id":"https:\/\/www.lmc.ca\/#website","url":"https:\/\/www.lmc.ca\/","name":"LMC Healthcare : Pour mieux comprendre et ma\u00eetriser votre diab\u00e8te","description":"Ing\u00e9nieurs conseils en conception","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lmc.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Person","@id":"https:\/\/www.lmc.ca\/#\/schema\/person\/0d459c76f19eec906969bebe87612783","name":"LMC Healthcare","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g","caption":"LMC Healthcare"},"url":"https:\/\/www.lmc.ca\/fr\/author\/andrea\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/posts\/60589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/comments?post=60589"}],"version-history":[{"count":0,"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/posts\/60589\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/media\/60590"}],"wp:attachment":[{"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/media?parent=60589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/categories?post=60589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lmc.ca\/fr\/wp-json\/wp\/v2\/tags?post=60589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}